MAPK3 and adenocarcinoma: We further demonstrated recovery of the ERK1/2 phosphorylation in patients diagnosed with advanced pT3 and pT4 adenocarcinoma with intratumoral or peritumoral invasion to the vasculature, perineural invasion, or metastasis in lymph nodes (Figure 1c–e).